SCHEMBL6420545

SCHEMBL6420545

O=C(Cl)c1cccc(Br)c1Br

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
ALOX15 P16050 1/20 0.45
PRNP P04156 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAOB P27338 1/20 0.37
MIF P14174 1/20 0.37
RAB9A P51151 1/20 0.36
GAA P10253 1/20 0.35
FABP4 P15090 1/20 0.35
TSHR P16473 1/20 0.34
ELANE P08246 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4728428 0.88 ALDH1A1 (0.50) ALDH1A1ALOX15PRNPMEN1KMT2A
SCHEMBL8495468 0.81 PRNP (0.50) ALDH1A1ALOX15PRNPMEN1KMT2A
SCHEMBL123057 0.81 ALDH1A1 (0.54) ALDH1A1ALOX15MEN1KMT2ANPC1
SCHEMBL4921450 0.80 ALDH1A1 (0.46) ALDH1A1ALOX15PRNPMEN1KMT2A
SCHEMBL28789921 0.80 ALDH1A1 (0.43) ALDH1A1ALOX15PRNPMEN1KMT2A
SCHEMBL7596116 0.80 ALDH1A1 (0.52) ALDH1A1ALOX15TSHRHPGDCES2
SCHEMBL1552127 0.80 ALDH1A1 (0.43) ALDH1A1ALOX15PRNPMEN1KMT2A
SCHEMBL11815709 0.79 ALDH1A1 (0.37) ALDH1A1ALOX15
SCHEMBL588389 0.79 PRNP (0.53) ALDH1A1ALOX15PRNPKMT2ASMN1; SMN2
SCHEMBL17938254 0.78 ALDH1A1 (0.63) ALDH1A1ALOX15MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731626-A1 PI3K INHIBITORS AND USE THEREOF Regor Pharmaceuticals, Inc. (US) 2026-04-29 EP disclosed
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis THE UNIVERSITY OF CHICAGO (US) 2025-04-22 US disclosed
WO-2024260464-A1 PI3K INHIBITORS AND USE THEREOF REGOR PHARMACEUTICALS, INC. (US) 2024-12-26 WO disclosed
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2024-12-19 US disclosed
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS THE UNIVERSITY OF CHICAGO (US) 2022-06-09 US disclosed
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2022-02-10 US disclosed
EP-3946301-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS The University of Chicago (US) 2022-02-09 EP disclosed
WO-2020206118-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2020-10-08 WO disclosed
WO-2020206109-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS THE UNIVERSITY OF CHICAGO (US) 2020-10-08 WO disclosed
EP-1554360-A2 ORGANIC ELECTROLUMINESCENT COMPOSITIONS 3M Innovative Properties Company (US) 2005-07-20 EP disclosed
WO-2004099338-A2 ORGANIC ELECTROLUMINESCENT COMPOSITIONS 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-11-18 WO disclosed
EP-1237839-A2 PROCESS FOR PRODUCING 3-BROMOBENZOYL HALIDES ALBEMARLE CORPORATION (US) 2002-09-11 EP disclosed
WO-2002057281-A2 AMINOGLYCOSIDES AS ANTIBIOTICS WAYNE STATE UNIVERSITY (US) 2002-07-25 WO disclosed
US-6271417-B1 Process for producing 3-bromobenzoyl halides ALBEMARBLE CORPORATION 2001-08-07 US disclosed
EP-1095005-A1 PREPARATION OF CARBOXYLIC COMPOUNDS AND THEIR DERIVATIVES ALBEMARLE CORPORATION (US) 2001-05-02 EP disclosed
WO-2001021565-A2 PROCESS FOR PRODUCING 3-BROMOBENZOYL HALIDES ALBEMARLE CORPORATION (US) 2001-03-29 WO disclosed
US-6096920-A LARGE-SCALE PRODUCTION OF CERTAIN AROMATICALLY-SUBSTITUTED ALIPHATIC CARBOXYLIC ACIDS AND THEIR ACID DERIVATIVES ALBEMARLE CORPORATION (US) 2000-08-01 US disclosed
WO-2000002840-A1 PREPARATION OF CARBOXYLIC COMPOUNDS AND THEIR DERIVATIVES ALBEMARLE CORPORATION (US) 2000-01-20 WO disclosed
EP-0332988-A2 2-Aryl-benzoxazoles and 2'-hydroxybenzanilides BAYER AG (DE) 1989-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A ALDH1A1 2857/4885ALOX15 3924/4885PRNP 4574/4885
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS MYLK, MFAP1, FIBP ALDH1A1 3220/4885ALOX15 3082/4885PRNP 4330/4885
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis MYLK, MFAP1, FIBP ALDH1A1 3220/4885ALOX15 3082/4885PRNP 4330/4885
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A ALDH1A1 2857/4885ALOX15 3924/4885PRNP 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.